Loading...
01/11 11:05
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
Revenue $7.3 million for Q2 2025 compared with $9.2 million for Q2 2024, a year-over-year decline primarily due to fewer capital system sales to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements.
Gross Profit $2.9 million for Q2 2025 compared with $5.4 million for Q2 2024, a decrease driven by lower sales and higher cost of service.
Gross Margin 39.7% for Q2 2025 versus 58.7% for Q2 2024, primarily driven by lower sales and higher cost of service.
General and Administrative Expense $2 million for Q2 2025 compared with $1.6 million for Q2 2024, reflecting higher professional fees and compensation.
Selling and Marketing Expense $1.4 million for Q2 2025 compared with $1 million for Q2 2024, an increase due to higher trade show expenses, higher costs related to clinical studies, and higher payroll costs due to an increase in headcount.
Research and Development Expense $1.5 million for Q2 2025 compared with $0.9 million for Q2 2024, primarily due to costs associated with ongoing product development and readiness for the anticipated TDI commercialization.
Net Loss $1 million or $0.06 per share for Q2 2025 compared with net income of $1.6 million or $0.10 per diluted share for Q2 2024.
Adjusted EBITDA Negative $1.8 million for Q2 2025 versus a positive $2.1 million for Q2 2024, reflecting higher operating expenses and lower revenue.
SRT-100 Vision: The product combines superficial radiotherapy with image-guided ultrasound for treating non-melanoma skin cancer. However, a proposed LCD may limit reimbursement for ultrasound usage, impacting demand.
TDI platform: The next-generation platform is under FDA review, with feedback expected later this year. Preparations for commercial deployment are ongoing.
International Expansion: Delivered 4 SRT systems to China, indicating growing demand. Achieved MDSAP certification, enabling access to markets in Brazil, Canada, Japan, and Australia.
U.S. Market Expansion: Broadened commercial footprint by partnering with Radiation Oncology Systems for hospital-based oncology segments.
FDA Contracts: Signed 5 new contracts and activated 4 sites in Q2. Treatment volume increased by 27% over Q1.
Sentinel Software: HIPAA-compliant platform enables remote diagnostics and data storage, enhancing operational efficiency.
Reimbursement Changes: Medicare proposed a new physician fee schedule that could increase reimbursement for SRT delivery, potentially transforming U.S. commercial strategy.
Skin Cancer Awareness: Collaborated with advocacy organizations to promote early detection and noninvasive treatment options.
Proposed Local Coverage Determination (LCD): The proposed LCD to limit reimbursement for the use of ultrasound imaging with the SRT-100 Vision system has caused a temporary stall in domestic sales momentum. This creates uncertainty in the market and could impact future sales and revenue.
Medicare Physician Fee Schedule: A proposed physician fee schedule by Medicare may alter demand for Sensus products. While it could increase reimbursement for certain codes, the uncertainty surrounding its implementation poses a risk to strategic planning and market positioning.
Revenue Decline: Revenues for Q2 2025 decreased to $7.3 million from $9.2 million in Q2 2024, primarily due to fewer capital system sales to a large customer. This decline in revenue impacts financial performance and operational stability.
Gross Margin Reduction: Gross margin dropped to 39.7% in Q2 2025 from 58.7% in Q2 2024, driven by lower sales and higher service costs. This reduction in profitability could affect the company’s ability to reinvest in growth initiatives.
Increased Operating Expenses: General and administrative expenses, selling and marketing expenses, and R&D expenses all increased year-over-year, driven by higher professional fees, trade show costs, clinical studies, and lobbying efforts. These rising costs could strain financial resources.
Net Loss: The company reported a net loss of $1 million in Q2 2025 compared to a net income of $1.6 million in Q2 2024. This shift to a loss position highlights financial challenges and operational inefficiencies.
Regulatory Uncertainty: The 510(k) resubmission for the next-generation TDI platform is still under FDA review, delaying potential commercialization and revenue generation from this product.
International Market Risks: While international sales are growing, reliance on markets like China introduces risks related to economic and regulatory conditions in those regions.
Proposed Medicare Physician Fee Schedule: Medicare proposed a physician fee schedule that could significantly increase reimbursement for the delivery of a code of SRT. This new outpatient CPT delivery code, if issued, is expected to improve SRT's positioning and encourage more physicians to adopt the technology.
International Expansion: Momentum is building internationally, supported by the recent MDSAP certification. This certification provides immediate access to markets in Brazil, Canada, Japan, and Australia, with potential revenue contributions expected as early as later this year.
Next-Generation TDI Platform: The 510(k) resubmission for the next-generation TDI platform remains under FDA review, with feedback anticipated later this year. Preparations for commercial deployment are ongoing, including refining training protocols and exploring flexible implementation models.
China Market Growth: Four systems were shipped to China in Q2, indicating significant sales growth and potential economic strengthening in the region.
The selected topic was not discussed during the call.
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
The earnings call summary reflects several concerns: declining revenue, increased operating expenses, and a net loss compared to the previous year. While management expects future profitability, lack of formal guidance and reliance on a few key customers pose risks. No shareholder return initiatives were announced, and competitive pressures remain. Despite some positive aspects like cash position and international expansion, the overall sentiment is negative, as financial metrics are weak, and uncertainties in market demand persist.
The earnings call reveals several concerns: a revenue decline, increased operating expenses, and a net loss, all of which are negative indicators. Additionally, the lack of a share repurchase program and competitive pressures in the market further dampen sentiment. Despite some positive aspects like the Fair Deal Agreement and potential international expansion, these are overshadowed by the financial and competitive challenges. The Q&A session did not alleviate these concerns, with management avoiding specific guidance. These factors suggest a negative stock price reaction in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
